Litcius/Paper detail

NADPH-Cytochrome P450 Reductase Ccr1 Is a Target of Tamoxifen and Participates in Its Antifungal Activity via Regulating Cell Wall Integrity in Fission Yeast

Qiannan Liu, Xiaoxu Guo, Guanglie Jiang, Guoxiang Wu, Miao Hao, Kun Liu, Si Chen, Norihiro Sakamoto, Takayoshi Kuno, Fan Yao, Yue Fang

2020Antimicrobial Agents and Chemotherapy19 citationsDOIOpen Access PDF

Abstract

Invasive fungal diseases are a leading cause of mortality among immunocompromised populations. Treatment is notoriously difficult due to the limited number of antifungal drugs as well as the emergence of drug resistance. Tamoxifen (TAM), a selective estrogen receptor modulator frequently used for the treatment of breast cancer, has been found to have antifungal activities and may be a useful addition to the agents used to treat fungal infectious diseases. However, the molecular mechanisms underlying its antifungal actions remain obscure.

Topics & Concepts

TamoxifenAntifungalBiologyEstrogen receptorPharmacologyAntiestrogenYeastAntifungal drugDrugCancerBreast cancerMicrobiologyBiochemistryGeneticsAntifungal resistance and susceptibilityFungal Infections and StudiesSynthesis and Biological Evaluation
NADPH-Cytochrome P450 Reductase Ccr1 Is a Target of Tamoxifen and Participates in Its Antifungal Activity via Regulating Cell Wall Integrity in Fission Yeast | Litcius